| Filed On | Filing |
|---|---|
| 03 Nov 2026 |
8-K: Other Events
Pursuant to the terms of the Indenture, dated March 17, 2026, by and between Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.; the “Company” or the “Registrant”) and U.S. Bank Trust Company, National Association (the “Indenture”), go... |
| 02 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more
Anti-Corruption Laws, Anti-Money Laundering Laws, Export Controls and Sanctions |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
Richmond, VA, October 29, 2026 – Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the third quarter ended September 30, 2026. |
| 15 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 15, 2026, Indivior Pharmaceuticals, Inc. (“Indivior”) held a special meeting of its stockholders (the “Indivior Special Meeting”). At the close of business on September 4, 2026, the record date for the Indivior Special Meeting... |
| 06 Oct 2026 |
8-K: Other Events
As previously reported, on August 1, 2026, Indivior Pharmaceuticals, Inc., a Delaware corporation (the “Indivior”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Supernus Pharmaceuticals, Inc., a Delaware cor... |
| 17 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Payment of Special Dividend Contingent upon Closing of the Pending Merger Transaction |
| 15 Sep 2026 |
8-K: Termination of a Material Definitive Agreement
PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE LIKELY TO CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. REDACTED MATERI... |
| 03 Aug 2026 |
8-K: Regulation FD Disclosure
Merger of Equals to Create a Diversified CNS Biopharmaceutical Leader with Significant Scale AUGUST 3, 2026 Exhibit 99.1 |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Richmond, VA, August 3, 2026 – Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the second quarter ended June 30, 2026, and raised its full-year 2026 financial guidance. |
| 03 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
[***] – Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and the registrant customarily and actually treats as private and confidential |
| 15 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The Company held a virtual annual meeting of stockholders on May 13, 2026, at 10:00 a.m. Eastern Time. A total of 121,922,058 shares of common stock of the Company were entitled to vote as of March 18, 2026, the record date for the Annua... |
| 04 May 2026 |
8-K: Regulation FD Disclosure; Other Events
RICHMOND, Va., May 4, 2026 – Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced that it has entered into a $175 million accelerated share repurchase agreement (the “ASR”) with Barclays Bank PLC. The ASR will be executed under... |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Richmond, VA, April 30, 2026 – Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the first quarter ended March 31, 2026, and raised its full-year 2026 financial guidance. |
| 17 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +2 more
The table of contents is empty. Heading styles must be applied in the document and be selected in the table of contents properties panel. |
| 13 Mar 2026 |
8-K: Other Events
Richmond, VA, March 12, 2026 – Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced the pricing of its offering of $450,000,000 aggregate principal amount of 0.625% convertible senior notes due 2031 (the “notes”) in a private of... |
| 12 Mar 2026 |
8-K: Other Events
Richmond, VA, March 12, 2026 – Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount of convertible senior notes due 2031 (th... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Non-GAAP Quarterly and Full-Year Net Income of $107 Million and $320 Million |
| 26 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +8 more
THIS FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT, dated as of January 21, 2026 (this “Amendment”), is made by and among RBP Global Holdings Limited, a limited company organized under the laws of England and Wales (the “Issuer”), Piper San... |
| 08 Jan 2026 |
8-K: Regulation FD Disclosure
Investor Presentation January 8, 2026 Indivior, Powering Recovery, Renewing Hope. Exhibit 99.2 |
| 22 Dec 2025 |
8-K: Regulation FD Disclosure
Richmond, VA, December 22, 2025 – Indivior PLC (Nasdaq: INDV) (“Indivior PLC” or the “Company”) today announced that it will be added to the S&P SmallCap 600® index, effective today. |
Loading...